The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus‐infected people who inject drugs in England
Addiction2019Vol. 114(6), pp. 1113–1122
Citations Over TimeTop 10% of 2019 papers
Graham I. Harrison, Karen F. Murray, Roxanne Gore, Penelope Lee, Aravamuthan Sreedharan, Paul Richardson, Amanda J. Hughes, Martin Wiselka, Will Gelson, Esther Unitt, Karen Ratcliff, Annette Orton, Kerry Trinder, Charlotte Simpson, Stephen Ryder, Sandra Oelbaum, Graham R. Foster, Archie Christian, Stuart Smith, Brian J. Thomson, Rosy Reynolds, Magdalena Harris, Matthew Hickman, William L. Irving
Abstract
Introducing a half-time facilitator into drug and alcohol clinics in England increased engagement of HCV-positive people who inject drugs with hepatitis C virus care pathways, with increased uptake also of testing, referral to hepatology and initiation of treatment.
Related Papers
- → Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels(2013)180 cited
- → Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection(2017)175 cited
- → High Prevalence of Hepatitis C Virus Type 5 in Central France Evidenced by a Prospective Study from 1996 to 2002(2004)54 cited
- → Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor(2016)30 cited
- → Treatment of Hepatitis C Virus in the Coinfected Patient(2003)3 cited